BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34422666)

  • 1. Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
    Hong R; Tan Su Yin E; Wang L; Zhao X; Zhou L; Wang G; Zhang M; Zhao H; Wei G; Wang Y; Wu W; Zhang Y; Ni F; Hu Y; Huang H; Zhao K
    Front Oncol; 2021; 11():713577. PubMed ID: 34422666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38467921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
    Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
    Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
    Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
    Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
    Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic tumor burden on baseline
    Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
    Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.